Eyepoint Pharmaceuticals (NASDAQ:EYPT) Stock Rating Lowered by Royal Bank Of Canada

Eyepoint Pharmaceuticals (NASDAQ:EYPT) was downgraded by stock analysts at Royal Bank Of Canada from a “moderate buy” rating to a “hold” rating in a research note issued to investors on Monday,Zacks.com reports.

A number of other research analysts also recently commented on the stock. Cantor Fitzgerald downgraded shares of Eyepoint Pharmaceuticals from an “overweight” rating to a “neutral” rating in a research report on Monday. HC Wainwright reaffirmed a “neutral” rating on shares of Eyepoint Pharmaceuticals in a research report on Tuesday. Guggenheim reiterated a “buy” rating and set a $68.00 price objective on shares of Eyepoint Pharmaceuticals in a research note on Wednesday, June 24th. Jefferies Financial Group dropped their price objective on shares of Eyepoint Pharmaceuticals to $8.00 and set a “buy” rating on the stock in a research note on Monday. Finally, Stifel Nicolaus assumed coverage on shares of Eyepoint Pharmaceuticals in a report on Thursday, July 16th. They set a “buy” rating and a $40.00 price objective on the stock. One equities research analyst has rated the stock with a Strong Buy rating, four have assigned a Buy rating, five have given a Hold rating and one has given a Sell rating to the company’s stock. According to data from MarketBeat.com, Eyepoint Pharmaceuticals has a consensus rating of “Hold” and an average price target of $28.11.

Eyepoint Pharmaceuticals Trading Up 12.3%

Shares of Eyepoint Pharmaceuticals stock opened at $5.47 on Monday. The firm has a market cap of $471.57 million, a P/E ratio of -1.46 and a beta of 1.76. Eyepoint Pharmaceuticals has a 12 month low of $3.95 and a 12 month high of $19.11. The stock’s fifty day moving average price is $12.97 and its 200-day moving average price is $13.55.

Eyepoint Pharmaceuticals (NASDAQ:EYPT) last released its quarterly earnings data on Wednesday, August 5th. The company reported ($1.09) earnings per share for the quarter, missing the consensus estimate of ($1.01) by ($0.08). Eyepoint Pharmaceuticals had a negative net margin of 10,994.73% and a negative return on equity of 135.81%. The firm had revenue of $0.51 million during the quarter, compared to the consensus estimate of $0.45 million. Analysts forecast that Eyepoint Pharmaceuticals will post -3.6 earnings per share for the current year.

Hedge Funds Weigh In On Eyepoint Pharmaceuticals

Institutional investors and hedge funds have recently added to or reduced their stakes in the stock. Janus Henderson Group PLC purchased a new stake in shares of Eyepoint Pharmaceuticals during the fourth quarter valued at about $53,658,000. Commodore Capital LP bought a new stake in shares of Eyepoint Pharmaceuticals in the 1st quarter valued at about $36,414,000. Paradigm Biocapital Advisors LP purchased a new position in shares of Eyepoint Pharmaceuticals in the 3rd quarter worth approximately $28,556,000. Orbimed Advisors LLC purchased a new position in shares of Eyepoint Pharmaceuticals in the 3rd quarter worth approximately $25,575,000. Finally, Suvretta Capital Management LLC raised its stake in shares of Eyepoint Pharmaceuticals by 26.4% during the 4th quarter. Suvretta Capital Management LLC now owns 7,827,685 shares of the company’s stock worth $143,012,000 after acquiring an additional 1,634,970 shares in the last quarter. Hedge funds and other institutional investors own 99.41% of the company’s stock.

Eyepoint Pharmaceuticals News Roundup

Here are the key news stories impacting Eyepoint Pharmaceuticals this week:

• Positive Sentiment: Citigroup maintained a Buy rating while lowering its price target to $17, implying substantial potential upside from current levels. Jefferies also retained a Buy rating, with an $8 target. Benzinga analyst coverage
• Positive Sentiment: Although DURAVYU missed the full-study primary endpoint, EyePoint said the drug was non-inferior to aflibercept in an ad hoc analysis excluding an asymmetric group of patients whose vision loss was unrelated to wet AMD. The trial also showed a 42% reduction in treatment burden, durable disease control, supplement-free treatment rates and a favorable redosing safety profile. EyePoint LUGANO trial announcement
• Neutral Sentiment: Unusual options activity was reported, with traders purchasing 3,011 call contracts, about 19% above average call volume. This may reflect speculative expectations for a recovery but does not change the trial outcome.
• Neutral Sentiment: Trading in EYPT was temporarily halted for news before the trial results were released, underscoring the market sensitivity surrounding the announcement.
• Negative Sentiment: The full LUGANO dataset missed the primary endpoint, triggering a roughly two-thirds collapse in the stock and raising questions about DURAVYU’s regulatory path and commercial prospects. The result was widely described as a late-stage trial failure. Reuters trial report
• Negative Sentiment: Analyst sentiment became more cautious: Cantor Fitzgerald downgraded EYPT to Neutral, while Chardan, RBC, JPMorgan and HC Wainwright maintained neutral or sector-perform views. Chardan cut its target to $5 from $65, and RBC and Chardan both set $5 targets, indicating limited near-term upside.

Eyepoint Pharmaceuticals Company Profile

Eyepoint Pharmaceuticals, Inc is a biopharmaceutical company focused on the development and commercialization of therapies for the treatment of ocular diseases. The company’s proprietary platform centers on sustained-release formulations designed to improve drug delivery to the posterior segment of the eye, addressing conditions that often require repeated intravitreal injections or intensive topical regimens. Eyepoint’s commercial strategy combines in-house sales and marketing capabilities with targeted partnerships to bring its therapies to ophthalmologists and retina specialists across the United States.

Eyepoint’s lead products include YUTIQ, a fluocinolone acetonide intravitreal implant indicated for the prevention of relapse in non-infectious uveitis affecting the posterior segment of the eye, and DEXYCU, a dexamethasone intraocular suspension approved for postoperative inflammation following ocular surgery.